Allogeneic hematopoieteic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis (MF), but it is still associated with significant risks and complications. One of these complications is poor graft function, but incidence and risk factors have not been studied yet. We retrospectively studied a cohort of 100 patients with primary MF or post-ET/PV MF who received a reduced-intensity HSCT in our center. The cumulative incidence of primary leukocyte engraftment was 98%. The cumulative incidence of poor graft function was 17% and all of the cases occurred before day 100 after HSCT at a median of 49 days (range 24-99 days). In the univariate analysis, age as continuous parameter (P = 0.05; hazard ratio 1042) and persistence of significant splenomegaly (defined as palpable splenomegaly of ⩾ 10 cm under costal margin) at d+30 after HSCT (33% vs 12%; P = 0.05) showed an increased cumulative incidence of poor graft function. In conclusion, the incidence of poor graft function after HSCT for MF is rather high, but did not influence survival. Persistence of splenomegaly after transplantation is a significant factor for poor graft function in myelofibrosis patients. Whether therapeutic reduction of splenomegaly before HSCT would result in a lower incidence of poor graft function should be investigated in future studies.
INTRODUCTION
Graft failure is a well-studied complication of hematopoieteic stem cell transplantation (HSCT). It can manifest as either lack of initial engraftment (primary graft failure) or loss of donor cells after initial established engraftment (graft rejection). The diagnosis of this form of graft failure is generally supported with the presence of recipient lymphocytes as well as reduction or absence of donor cells in bone marrow. 1 According to earlier studies, the following factors may be associated with primary graft failure or graft rejection: HLA disparity between recipient and donor, 2 pre-sensitizing of patients with blood transfusions, 3,4 T-celldepleted grafts, 5 reduced-intensity conditioning (RIC) 6 major AB0 mismatch, 7 low stem cell dose. 8 Poor graft function is another complication of HSCT that may be accompanied by serious morbidity due to infections, bleeding and secondary transfusionrelated iron overload. In contrast to graft failure a complete donor cell chimerism is present. Several studies based on cohorts treated with myeloablative conditioning reported an incidence of about 5% [9] [10] [11] but the definition of poor graft function differed substantially between those studies. Neither the European Society of Blood and Marrow Transplantation (EBMT) nor the Center of International Blood and Marrow Transplant Research (CIBMTR) provided a valuable definition. More recently, a useful definition was reported by Klyuchnikov et al. 12 and Stasia et al. 13 where poor graft function was defined as cytopenia in at least two hematopoietic lines (neutrophil count ⩽ 1.5 × 10 9 /L, platelet count ⩽ 30 × 10 9 /L, Hb ⩽ 8.5 g/dL) for at least two consecutive weeks beyond day +14 after achieving a documented engraftment in the presence of full donor chimerism and in the absence of severe GvHD, CMV reactivation, relapse or drug-related myelosuppression, but hypocellular bone marrow. To our knowledge, there are no data showing the incidence of this complication after RIC-HSCT for primary myelofibrosis (PMF) but there are some indicators that it may be high. In a retrospective study from two centers that included 32 patients with poor graft function treated with CD34 + -selected stem cell boost, 44% were transplanted for myelofibrosis. 12 In another retrospective study from our center that included 139 myelofibrosis patients treated with RIC-HSCT, we found that 13 patients (9%) required a stem cell boost during the follow-up. 14 PMF and post polycythemia vera (post-PV MF) or essential thrombocythemia (post-ET MF) are myeloproliferative neoplasm characterized by a clonal stem cell-derived myeloproliferation and a reactive bone marrow fibrosis with osteosclerosis, extramedullary hematopoiesis and increased cytokine release. Allogeneic HSCT is a curative treatment for myelofibrosis, but the application of HSCT in PMF setting was limited mainly because of concerns regarding advanced bone marrow fibrosis, which may complicate engraftment of hematopoietic stem cells. [15] [16] [17] [18] Using the intensity-reduced (RIC-HSCT) conditioning regimens, [19] [20] [21] HSCT had become a wellestablished curative treatment for high-risk myelofibrosis patients with acceptable post-transplant non-relapse mortality.
The current study aimed at estimating the incidence of poor graft functions in myelofibrosis patients treated with RIC-ASCT in our center and to analyze the predicting risk factors of this complication.
Declaration of Helsinki. We reviewed the records of a 119 patients with histologically proven primary or post ET/PV MF who were treated with HSCT after RIC in our center between December 1999 and March 2010. To obtain the incidence of poor graft function after HSCT for MF, we identified the patients for whom blood counts and transfusion needs were completely documented for the entire follow-up period after HSCT. A total of 100 patients with complete data set were identified. We have comprehensively reviewed the data of those patients to find those who developed poor graft function after HSCT. As mentioned above, in the current study poor graft function was defined as follows: cytopenia in at least two hematopoietic lines (neutrophil count ⩽ 1.5 × 10 9 /L, platelet count ⩽ 30 × 10 9 /L, Hb ⩽ 8.5 g/dL) for at least two consecutive weeks beyond day +14 after achieving a documented engraftment in the presence of full donor chimerism and in the absence of severe GvHD, CMV reactivation, relapse or drug-related myelosuppression.
Treatment plan
Most of the patients received RIC regimen that consisted of busulfan, 10 mg/kg body weight (BW) orally (or busulfan, intravenously, in equivalent doses) given in 10 doses over 3 days; fludarabine, 180 mg/m 2 BSA, given as 30 mg/m 2 over 6 days. Six patients were treated with treosulfan 36 g/m 2 BSA intravenously given in 3 doses over 3 days, fludarabine 180 mg/m 2 BSA, given as 30 mg/m 2 over 6 days. Four patients were in blast-phase disease before ASCT and received a conditioning with FLAMSA-protocol as follows: induction phase using fludarabine 30 mg/m 2 BSA, cytarabine 2000 mg/m 2 BSA and amsacrine 100 mg/m 2 BSA on days − 11 to − 8 followed after 3 days of rest by RIC consisting of BU/FLU (busulfan 0.8 mg/kg BW four times daily on day − 4 and − 3, and 0.8 mg/kg BW two times on day − 2, fludarabine 30 mg/m 2 BSA on days − 5 to − 4. Antilymphocyte-globulin ATG (ATG-Fresenius, Gräfelfing, Germany) was given as follows: 3 × 10 mg/kg BW for related transplantation or 3 × 20 mg/ kg BW for unrelated transplantation. Stem cell source was peripheral stem cells in all cases.
The GvHD prophylaxis consisted of cyclosporine at a dose of 3 mg/kg BW as continuous infusion starting at day +1. The cyclosporine dose was adjusted according to the serum level of 200 ng/mL. If no GvHD occurs, cyclosporine was tapered and discontinued after day 180. Further GvHD prophylaxis consisted of either methotrexate (10 mg/m 2 BSA) at days +1, +3 and +6, or mycophenolate mofetil until day +30.
Support with G-CSF was started on day +5 after ASCT and continued until leukocyte engraftment.
Only CMV-positive patients with stable haematopoiesis received valganciclovir prophylactically, other CMV-positive patients were treated by a pre-emptive strategy.
Statistical analysis
Endpoint was incidence of poor graft function. Characteristics of patients were expressed as median and range for continuous variables and frequencies for categorical variables. Categorical data were compared using χ 2 -test or Fisher exact test. Survival curves were estimated by the Kaplan-Meier method. The log-rank test was used to estimate the incidence of poor graft function to account for competing risk. For incidence of poor graft function: primary graft failure, non-relapse mortality, relapses until d+120 post ASCT were considered competing events. The Gray test was used to compare the cumulative incidence curves for subgroups.
Univariate analysis was performed using Fine and Gray proportional hazard model: the included factors are summarized in Table 1 .
Most calculations were performed with SPSS Version 15; the competing risk analyses were done with ACCorD (V Gebski, NHMRC Clinical Trials Center, University of Sydney).
RESULTS
Data of 100 patients could be pooled to evaluate risk factors for poor graft function. The cumulative incidence of leukocyte engraftment was 98% (confidence interval (CI): 93-100%) and only two patients had a primary graft failure. 
According to the definition mentioned above, 17 patients fulfilled the criteria of poor graft function with a cumulative incidence of 17% (CI: 9-25%; Figure 1 ). Poor graft function occurred relatively early after HSCT at a median of 49 days (range 24-99 days).
The factors listed in Table 1 were included in the univariate model to detect risk factors for poor graft function.
Age as continuous parameter was associated with increased cumulative incidence of poor graft function after HSCT (P = 0.05; hazard ratio 1042). Patients with palpable spleen of ⩾ 10 cm under the left costal margin before HSCT had a trend toward increased incidence of poor graft function (26% vs 13%; P = 0.13). Importantly, the incidence of poor graft function was significantly increased in those patients who still had a palpable spleen of ⩾ 10 cm at d+30 after HSCT (33% vs 12%; P = 0.05; Figure 2) . Further, male patients (23% vs 9%; P = 0.08) showed a trend toward increased cumulative incidence of poor graft function. Remarkably, grade of fibrosis in bone marrow before HSCT, at d+30 after HSCT, and grade of regression of the marrow fibrosis at d+30 were not predictive for poor graft function. The 3-year estimated overall survival for the entire group was 66% (95% CI: 54-78%) and did not differ between patients with or without poor graft function (64% vs 66%, P = 0.74; Figure 3) .
In only one patient, did the poor graft function episode resolve spontaneously without any medical intervention. Four patients were treated successfully with growth factors. One patient who had a complete molecular and histological remission in bone marrow but a persisting massive splenomegaly at the time of poor graft function underwent a splenectomy and recovered from poor graft function thereafter. Nine patients were treated successfully with CD34 + -selected stem cell boost as recently described. 12 One patient had a second transplantation and died due to fulminant fungal infection. One patient reactivated a pre-existing fungal infection and died before receiving specific treatment.
DISCUSSION
Poor graft function is a type of graft failure characterized by cytopenias without loss of full donor chimerism and this type is less well studied. This complication can be primary without an evident triggering factor and can be secondary to viral infections, septicemia and drug toxicity. 22, 23 Estimating incidence and risk factors of poor graft function in patients transplanted for myelofibrosis was the aim of our study.
In the current study, the cumulative incidence of primary engraftment was favorably high in spite of marrow fibrosis associated with the underlying disease and the use of RIC, most probably due to adequate in vivo T-cell depletion with ATG and the immune suppressive effect of fludarabine in the conditioning regimen. However, the incidence of poor graft function seems to be significant in the study population. To our knowledge, there are no previous data estimating the real incidence of poor graft function after HSCT in general or in the setting of myelofibrosis. According to the current analysis, older male patients, patients with large splenomegaly before HSCT or those without significant regression of spleen size at d+30 could be at risk to develop this complication after HSCT.
Considering the results in general, we may assume that degree of splenomegaly seems to have an important role in maintaining engraftment in the long term. Remarkably all patients with available measurement of spleen size at the time of poor graft function were still having a significant splenomegaly at this time point. This may lead to the assumption that pancytopenia could be caused or at least aggravated by sequestration in the enlarged spleen. Because all of the patients with enlarged spleen size after HSCT had alsoand most likely even greater-enlarged spleen size before transplantation, it is very likely that poor graft function resulted from sequestration of transplanted CD34 + cells in the spleen during stem cell transplantation, leading to hypocellular bone marrow. It should be noted that spleen size more than 10 cm was noted in 56% before transplant and in only 21% post transplant and both variables resulted in a comparable incidence of poor graft function in comparison with non-enlarged spleen size (26% vs 13% and 33% vs 12%), but only the latter one was significant. None of the patients with splenectomy before transplant experienced poor graft function and none of the patients with enlarged spleen size after HSCT but with normal cellularity in bone marrow experienced cytopenia in the absence of severe GvHD, CMV reactivation, relapse or drug-related myelosuppression.
None of the patients with poor graft function had a manifest disease relapse/progression at the time of poor graft function event but most of them may still have some degree of the disease in the marrow biopsy which is not unusual according to our previous data. 24 Whether disease residues in marrow or in spleen could interfere with haematopoiesis beyond the time of primary engraftment either through impaired microenvironment or through shedding low amounts of inhibiting cytokines is not clear and should be investigated in future studies. A very interesting recent study evaluated risk factors for poor graft function after HSCT for AML, chronic myelomonocytic leukemia and myelodysplastic syndrome (MDS)-but not PMF-revealed a significant role of underlying disease. Patients with MDS and chronic myelomonocytic leukemia had an increased risk for poor graft function compared with others with acute leukemia. Furthermore, flowcytometric analysis of bone marrow in affected patients revealed a significant reduction in endosteal cells, perivascular cells and endothelial progenitor cells compared with controls suggesting a possible role of the microenvironment compartment in the bone marrow. 22 If such changes could be detected in patients with PMF and poor graft function after HSCT have to be elucidated. Notable, patients with poor graft function had similar 3-year overall survival than patients without poor graft function (64% vs 66%), which may be due to successful treatment of poor graft function, mainly by CD34-selected stem cell boost, but highlighted that poor graft function may result in a higher morbidity but not mortality.
We can assume that the current study is the first to evaluate systematically the incidence and risk factors of this important complication after HSCT for myelofibrosis. Our results are shedding more light on the predisposing conditions of this complication, especially the impact of splenomegaly associated with the underlying disease. However, our study had several limitations: even if nearly 90% received a busulfan-based reducedconditioning regimen, the study was performed retrospectively and the spleen size was measured mainly by physical examination. In this study, none of the patients had received ruxolitinib before transplantation. In the era of JAK2 inhibitors, many patients are now receiving those drugs before transplantation to reduce pruritus, spleen size or to eliminate constitutional symptoms. Whether JAK inhibitor treatment before HSCT would interfere with the predisposing factors for poor graft function and result in reduction in its incidence rates stay to be evaluated in future studies. Overall, the relatively high incidence of poor graft function observed in patients with myelofibrosis after allogeneic stem cell transplantation is mainly caused by (i) extensive splenomegaly before transplantation, which may result in sequestration of transplanted CD34 + cells resulting in hypocellular bone marrow and (ii) persistence of splenomegaly posttransplant, which aggravate the existing peripheral cytopenia by sequestration of peripheral blood cells. 
